A general route to a series of novel imidazobenzazepines that are ''carba'' analogs of the TIBO class of non-nucleoside HIV-1 reverse transcriptase inhibitors has been developed. A pair of allyl side-chain containing compounds were found to have significant HIV-1 inhibitory activity.